#United States #New York #Class Action #Securities Fraud #Actinium Pharmaceuticals

Actinium Pharmaceuticals Faces Securities Fraud Class Action Lawsuit

Actinium Pharmaceuticals, Inc. is currently embroiled in a class action lawsuit concerning alleged securities fraud. Investors are advised to be aware of this proceeding as the deadline for filing claims approaches. The law firm Levi & Korsinsky, LLP has made announcements to inform investors about their rights related to this case. In this article, we will delve into the implications of the lawsuit, the background of the claims, and the critical steps required to participate in the proceedings.

Overview of the Class Action Lawsuit

The lawsuit aims to recover financial losses for investors adversely affected by the alleged fraud during a specific period, from October 31, 2022, to August 2, 2024. Levi & Korsinsky has outlined pertinent details for those who believe they might be impacted by these actions, indicating a structured path toward obtaining compensation for losses sustained during the defined timeline.

Allegations Against Actinium Pharmaceuticals

The crux of the allegations rests in claims that the company misrepresented critical data related to its Phase 3 Sierra trial and the approval process for its targeted radiotherapy treatment, Iomab-B. Specifically, the complaint suggests that:

1. The data from the Sierra trial was unlikely to meet FDA requirements.
2. Subsequent analyses provided to the FDA, purportedly showing an improvement in overall survival rates, would similarly fail to satisfy regulatory guidelines.
3. Consequently, the FDA might refuse to review or approve the Iomab-B application.
4. Thus, the positive statements made by the defendants regarding Actinium's business prospects were materially misleading and lacked a reasonable foundation.

These claims highlight significant concerns regarding transparency, the communication of critical trial data, and overall investor trust.

Important Dates and Next Steps

Investors with losses during the relevant period have until May 27, 2025, to act. Those interested in becoming the lead plaintiff or simply seeking more information about the process are urged to make contact. It’s important to note that one does not need to serve as a lead plaintiff to partake in any recovery; this may be done without incurring any costs.

Individuals can reach out to Levi & Korsinsky through various means, including via email or phone, to discuss their circumstances and learn about participating in the class action. The firm emphasizes that there are no obligations or fees associated with engaging in this process for eligible class members.

Why Levi & Korsinsky?

Levi & Korsinsky has built a reputation over 20 years for securing substantial settlements for shareholders in complex securities litigation. The firm boasts a team dedicated to achieving optimal results for their clients, ensuring that investor rights are upheld in challenging situations. Past successes include numerous high-stakes cases, solidifying their position among the top firms for handling securities fraud claims in the United States.

Conclusion

For investors in Actinium Pharmaceuticals, being informed and proactive is crucial in light of the ongoing class action lawsuit. Those affected should not hesitate to contact Levi & Korsinsky to safeguard their interests and explore avenues for potential recovery. As the deadline looms, staying informed and prepared is essential for navigating this complex legal landscape. The road ahead may seem daunting, but having experienced legal representation can significantly impact the outcome for affected investors.

For further information, reach out to Levi & Korsinsky, LLP at:

• - Email: info@zlk.com
• - Phone: (212) 363-7500

Stay abreast of the developments in this case to understand your rights and options as an Actinium investor.